Literature DB >> 24935406

Effects of schizophrenia risk variation in the NRG1 gene on NRG1-IV splicing during fetal and early postnatal human neocortical development.

Clare Paterson, Yanhong Wang, Joel E Kleinman, Amanda J Law.   

Abstract

OBJECTIVE: Neuregulin 1 (NRG1) is a multifunctional neurotrophin that mediates neurodevelopment and schizophrenia risk. The NRG1 gene undergoes extensive alternative splicing, and association of brain NRG1 type IV isoform expression with the schizophrenia-risk polymorphism rs6994992 is a potential mechanism of risk. Novel splice variants of NRG1-IV (NRG1-IVNV), with predicted unique signaling capabilities, have been cloned in fetal brain tissue. The authors investigated the temporal dynamics of transcription of NRG1-IVNV, compared with the major NRG1 isoforms, across human prenatal and postnatal prefrontal cortical development, and they examined the association of rs6994992 with NRG1-IVNV expression.
METHOD: NRG1 type I-IV and NRG1-IVNV isoforms were evaluated with quantitative real-time polymerase chain reaction in human postmortem prefrontal cortex tissue samples at 14 to 39 weeks gestation and postnatal ages 0-83 years. The association of rs6994992 genotype with NRG1-IVNV expression and the subcellular distribution and proteolytic processing of NRG1-IVNV isoforms were also determined.
RESULTS: Expression of NRG1 types I, II, and III was temporally regulated during prenatal and postnatal neocortical development. NRG1-IVNV was expressed from 16 weeks gestation until age 3. Homozygosity for the schizophrenia risk allele (T) of rs6994992 conferred lower cortical NRG1-IVNV levels. Assays showed that NRG1-IVNV is a novel nuclear-enriched, truncated NRG1 protein resistant to proteolytic processing.
CONCLUSIONS: To the authors' knowledge, this study provides the first quantitative map of NRG1 isoform expression during human neocortical development and aging. It identifies a potential mechanism of early developmental risk for schizophrenia at the NRG1 locus, involving a novel class of NRG1 proteins.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24935406      PMCID: PMC4330971          DOI: 10.1176/appi.ajp.2014.13111518

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  50 in total

Review 1.  Trajectories of brain development: point of vulnerability or window of opportunity?

Authors:  Susan L Andersen
Journal:  Neurosci Biobehav Rev       Date:  2003 Jan-Mar       Impact factor: 8.989

2.  Structural and functional aspects of the multiplicity of Neu differentiation factors.

Authors:  D Wen; S V Suggs; D Karunagaran; N Liu; R L Cupples; Y Luo; A M Janssen; N Ben-Baruch; D B Trollinger; V L Jacobsen
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

3.  Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia.

Authors:  Dawei Li; David A Collier; Lin He
Journal:  Hum Mol Genet       Date:  2006-05-10       Impact factor: 6.150

4.  Association analysis of Neuregulin 1 candidate regions in schizophrenia and bipolar disorder.

Authors:  Rosie M Walker; Andrea Christoforou; Pippa A Thomson; Kevin A McGhee; Alan Maclean; Thomas W Mühleisen; Jana Strohmaier; Vanessa Nieratschker; Markus M Nöthen; Marcella Rietschel; Sven Cichon; Stewart W Morris; Omer Jilani; David Stclair; Douglas H Blackwood; Walter J Muir; David J Porteous; Kathryn L Evans
Journal:  Neurosci Lett       Date:  2010-05-07       Impact factor: 3.046

5.  Temporal dynamics and genetic control of transcription in the human prefrontal cortex.

Authors:  Carlo Colantuoni; Barbara K Lipska; Tianzhang Ye; Thomas M Hyde; Ran Tao; Jeffrey T Leek; Elizabeth A Colantuoni; Abdel G Elkahloun; Mary M Herman; Daniel R Weinberger; Joel E Kleinman
Journal:  Nature       Date:  2011-10-26       Impact factor: 49.962

6.  Lack of association to a NRG1 missense polymorphism in schizophrenia or bipolar disorder in a Costa Rican population.

Authors:  Emily Moon; Brandi Rollins; Andrea Mesén; Adolfo Sequeira; Richard M Myers; Huda Akil; Stanley J Watson; Jack Barchas; Edward G Jones; Alan Schatzberg; William E Bunney; Lynn E DeLisi; William Byerley; Marquis P Vawter
Journal:  Schizophr Res       Date:  2011-07-13       Impact factor: 4.939

Review 7.  Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology.

Authors:  Paul J Harrison; Amanda J Law
Journal:  Biol Psychiatry       Date:  2006-01-25       Impact factor: 13.382

8.  Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons.

Authors:  Lei Wen; Yi-Sheng Lu; Xin-Hong Zhu; Xiao-Ming Li; Ran-Sook Woo; Yong-Jun Chen; Dong-Min Yin; Cary Lai; Alvin V Terry; Almira Vazdarjanova; Wen-Cheng Xiong; Lin Mei
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-29       Impact factor: 11.205

9.  Neurotrophins induce neuregulin release through protein kinase Cdelta activation.

Authors:  Raymond M Esper; Jeffrey A Loeb
Journal:  J Biol Chem       Date:  2009-07-31       Impact factor: 5.157

10.  Confirmation and refinement of an 'at-risk' haplotype for schizophrenia suggests the EST cluster, Hs.97362, as a potential susceptibility gene at the Neuregulin-1 locus.

Authors:  A P Corvin; D W Morris; K McGhee; S Schwaiger; P Scully; J Quinn; D Meagher; D St Clair; J L Waddington; M Gill
Journal:  Mol Psychiatry       Date:  2004-02       Impact factor: 15.992

View more
  9 in total

1.  Temporal, Diagnostic, and Tissue-Specific Regulation of NRG3 Isoform Expression in Human Brain Development and Affective Disorders.

Authors:  Clare Paterson; Yanhong Wang; Thomas M Hyde; Daniel R Weinberger; Joel E Kleinman; Amanda J Law
Journal:  Am J Psychiatry       Date:  2016-10-24       Impact factor: 18.112

2.  Epigenetic meta-analysis across three civilian cohorts identifies NRG1 and HGS as blood-based biomarkers for post-traumatic stress disorder.

Authors:  Monica Uddin; Andrew Ratanatharathorn; Don Armstrong; Pei-Fen Kuan; Allison E Aiello; Evelyn J Bromet; Sandro Galea; Karestan C Koenen; Benjamin Luft; Kerry J Ressler; Derek E Wildman; Caroline M Nievergelt; Alicia Smith
Journal:  Epigenomics       Date:  2018-11-20       Impact factor: 4.778

3.  Behavioral, Neurophysiological, and Synaptic Impairment in a Transgenic Neuregulin1 (NRG1-IV) Murine Schizophrenia Model.

Authors:  Francesco Papaleo; Feng Yang; Clare Paterson; Sara Palumbo; Gregory V Carr; Yanhong Wang; Kirsten Floyd; Wenwei Huang; Craig J Thomas; Jingshan Chen; Daniel R Weinberger; Amanda J Law
Journal:  J Neurosci       Date:  2016-04-27       Impact factor: 6.167

4.  Temporal Dynamics of the Neuregulin-ErbB Network in the Murine Prefrontal Cortex across the Lifespan.

Authors:  Clare Paterson; Brooke Cumming; Amanda J Law
Journal:  Cereb Cortex       Date:  2020-05-14       Impact factor: 5.357

Review 5.  Recent genetic findings in schizophrenia and their therapeutic relevance.

Authors:  Paul J Harrison
Journal:  J Psychopharmacol       Date:  2014-10-14       Impact factor: 4.153

6.  Splicing QTL of human adipose-related traits.

Authors:  Liang Ma; Peilin Jia; Zhongming Zhao
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

Review 7.  Neurochemical Alterations in Sudden Unexplained Perinatal Deaths-A Review.

Authors:  Nazeer Muhammad; Muhammad Sharif; Javeria Amin; Riffat Mehboob; Syed Amir Gilani; Nargis Bibi; Hasnain Javed; Naseer Ahmed
Journal:  Front Pediatr       Date:  2018-01-25       Impact factor: 3.418

8.  Metabotropic glutamate receptor 3 (mGlu3; mGluR3; GRM3) in schizophrenia: Antibody characterisation and a semi-quantitative western blot study.

Authors:  Aintzane García-Bea; Mary A Walker; Thomas M Hyde; Joel E Kleinman; Paul J Harrison; Tracy A Lane
Journal:  Schizophr Res       Date:  2016-04-27       Impact factor: 4.939

9.  Overexpression of Neuregulin 1 Type III Confers Hippocampal mRNA Alterations and Schizophrenia-Like Behaviors in Mice.

Authors:  Juan C Olaya; Carrie L Heusner; Mitsuyuki Matsumoto; Duncan Sinclair; Mari A Kondo; Tim Karl; Cynthia Shannon Weickert
Journal:  Schizophr Bull       Date:  2018-06-06       Impact factor: 9.306

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.